Categories Earnings, Finance

Mastercard (MA) earnings preview: Strong retail sales to fuel Q3 results

Mastercard Incorporated (NYSE: MA) is slated to report third quarter 2019 earnings results on Tuesday, October 29, before the market opens. Analysts have forecast earnings of $2.01 per share. This compares to EPS of $1.78 reported a year earlier. Revenue is projected to increase over 13% to $4.42 billion.

The topline numbers are likely to benefit from higher retail spending, healthy ecommerce growth and an increase in digital payments. The strong double-digit growth in switched transactions and cross-border volume seen last quarter is expected to continue this time as well, fueling revenue growth. Mastercard will also benefit from its various acquisitions and strategic partnerships.   

Mastercard reports Q2 2019 earnings results

However, higher incentives as well as negative impacts from foreign exchange are expected to dampen the quarterly results. Increased spending, particularly in marketing and promotion, is also likely to weigh on earnings. Last quarter, operating expenses increased 1% on a currency neutral basis.

In the second quarter of 2019, Mastercard topped revenue and earnings expectations. Revenues increased 12% to $4.1 billion while adjusted EPS grew 14% to $1.89. Switched transactions were up 18%. On a local currency basis, cross-border volume rose 16% while both gross dollar volume and purchase volume increased 13%.

Also read: Mastercard Q2 2019 Earnings Conference Call Transcript

Shares of Mastercard have gained 28% so far this year. The stock has a strong Buy rating and the average price target is $317.31.

Mastercard’s competitor Visa (NYSE: V) reported Q4 2019 earnings results on Thursday, beating both revenue and profit expectations.

Browse through our earnings calendar and get all scheduled earnings announcements, analyst/investor conference and much more!

Most Popular

Intensity Therapeutics is establishing a new field of localized cancer reduction: CEO

Intensity Therapeutics, Inc. (NASDAQ: INTS) is a clinical biotechnology company engaged in the discovery development, and commercialization of first-in-class cancer drugs that attenuate tumors with minimal side effects while training

INTU Earnings: Intuit Q1 2025 adj. profit rises on higher revenues

Financial technology company Intuit Inc. (NASDAQ: INTU) Thursday announced results for the first quarter of 2025, reporting a modest increase in adjusted earnings. The Mountain View-headquartered company’s first-quarter revenue came

Riding the AI wave, Nvidia looks set to stay on the high-growth path

After delivering strong results for the third quarter, Nvidia Corporation (NASDAQ: NVDA) this week said the launch of its new-generation Blackwell chip is on track. The company is thriving on

Add Comment
Loading...
Cancel
Viewing Highlight
Loading...
Highlight
Close
Top